The polyphenol quercetin induces cell death in leukemia by targeting epigenetic regulators of pro-apoptotic genes

Marisa Claudia Alvarez, Victor Maso, Cristiane Okuda Torello, Karla Priscilla Ferro and Sara Teresinha Olalla Saad*

Background: In the present study, we investigated the molecular mechanisms underlying the pro-apoptotic effects of quercetin (Qu) by evaluating the effect of Qu treatment on DNA methylation and posttranslational histone modifications of genes related to the apoptosis pathway. This study was performed in vivo in two human xenograft acute myeloid leukemia (AML) models and in vitro using HL60 and U937 cell lines.

Results: Qu treatment almost eliminates DNMT1 and DNMT3a expression, and this regulation was in part STAT-3 dependent. The treatment also downregulated class I HDACs. Furthermore, treatment of the cell lines with the proteasome inhibitor, MG132, together with Qu prevented degradation of class I HDACs compared to cells treated with Qu alone, indicating increased proteasome degradation of class I HDACs by Qu. Qu induced demethylation of the pro-apoptotic BCL2L11, DAPK1 genes, in a dose- and time-dependent manner. Moreover, Qu (50 μmol/L) treatment of cell lines for 48 h caused accumulation of acetylated histone 3 and histone 4, resulting in three- to ten fold increases in the promoter region of DAPK1, BCL2L11, BAX, APAF1, BNIP3, and BNIP3L. In addition, Qu treatment significantly increased the mRNA levels of all these genes, when compared to cells treated with vehicle only (control cells) (*p < 0.05).

Conclusions: In summary, our results showed that enhanced apoptosis, induced by Qu, might be caused in part by its DNA demethylating activity, by HDAC inhibition, and by the enrichment of H3ac and H4ac in the promoter regions of genes involved in the apoptosis pathway, leading to their transcription activation.

Keywords: Quercetin, HDACs, DNMTs, Epigenetics, Leukemia

Background

The myelodysplastic syndromes (MDSs) are a group of diverse and heterogeneous disorders characterized by clonal proliferation, bone marrow failure, and an increased risk of the development of acute myelogenous leukemia (AML) [1]. Leukemia has traditionally been considered to be the consequence of genetic alterations; however, in recent years, a body of evidence has demonstrated that the neoplastic phenotypes, including leukemia, may also be mediated by epigenetic alterations [2–4]. Epigenetics, broadly, refers to stimuli-triggered changes in gene expression due to processes that arise independent of changes in the underlying DNA sequence. Some of these processes include DNA methylation [5], histone modifications and chromatin-remodeling proteins [6], and DNA silencing by noncoding RNAs (ncRNA) [7]. The reversibility of epigenetics makes this mechanism a potential target for novel therapeutic approaches.

Quercetin (Qu) is an important dietary flavonoid, present in different vegetables, fruits, nuts, tea, red wine, and propolis [8–10]. Its study as potential therapeutic agent is assuming importance considering its involvement in the suppression of many tumor-related processes including oxidative stress, apoptosis, proliferation, and metastasis. Qu has also received attention as a pro-apoptotic flavonoid with a specific and almost exclusive effect on tumor cell lines rather than normal, non-transformed cells [11].

A previous study from our group showed that Qu caused pronounced apoptosis in leukemia cells, in vivo and in vitro (xenograft model), followed by BCL-2,
BCL-XL, MCL-1 downregulation, BAX upregulation, and mitochondrial translocation, triggering cytochrome c release and caspase activation [12]. In the present study, we investigated the molecular mechanisms underlying the pro-apoptotic effects of Qu by evaluating the effect of Qu treatment on DNA methylation and posttranslational histone modifications of genes related to the apoptosis pathway. Qu treatment of the myeloid leukemia cells, in vitro or in a human tumor xenograft, induced apoptosis, in part, through the reversal of epigenetic alterations.

Results
Gene-specific promoter methylation of apoptosis-related genes
We examined the DNA methylation status at the promoter CpG islands of 24 apoptosis-related genes in the HL60 cell line. Of the 24 genes assayed in the cell line, the extent of promoter methylation in five genes (BCL2L11, DAPK1, HKR, TNFRSF21, TNFRSF25) exceeded 90% (Fig. 1a). In order to determine whether quercetin affected CpG methylation, we further validated the promoter methylation of BCL2L11 and DAPK1 by MSP-PCR in samples treated with 50 and 75 μmol/L of Qu for 48 and 72 h. After 72 h of Qu treatment, there was partial demethylation of BCL2L11 and DAPK1 gene promoters in HL60 cells (Fig. 1b, c). The partial demethylation of DAPK1 promoter was confirmed by bisulfite sequencing (Fig. 1d-f). Concentrations of 1 and 2 μM concentration of 5-aza-dC were chosen as positive control. The U937 cell line was also treated with Qu (same concentrations and period of time as for HL60 cells). This cell line was unmethylated in the promoter region of DAPK1 and hemimethylated in the promoter region of BCL2L11. No demethylation was observed after Qu treatment (Fig. 1c).
Quercetin downregulates DNMTs and STAT3
Since Qu induced partial demethylation in the promoter regions of highly methylated genes, Western blot analyses using anti-DNMT1 (DNA methyltransferase 1) and anti-DNMT3a (DNA methyltransferase 3a) antibodies were performed. Qu treatment decreased the levels of both proteins. Next, since the STAT3 pathway directly regulates DNMTs [13], we investigated whether Qu treatment modulates these proteins. Western blot analysis, RT-PCR, and confocal microscopy showed that Qu treatment downregulated STAT3 expression and phosphorylation ($p < 0.05$). These data provide evidence that Qu downregulates DNMTs through STAT3 pathway (Fig. 2a–c).

Quercetin induces H3 and H4 global acetylation
Like DNA methylation, the acetylation or methylation of histone proteins comprises major epigenetic processes on the chromatin structure, altering nucleosomal architecture and leading to gene activation or repression. In order to determine whether Qu also affects histones, we determined the effect of Qu treatment on global acetylation of histones 3 and 4. For this purpose, Western blotting of the acid-extracted proteins of the HL60 cell line were exposed to 50 μmol/L Qu for 48 h and western blotting was performed. After Qu treatment, a global increase in H3ac and H4ac was observed compared to cells treated with vehicle only (Fig. 2d).

Fig. 2 Quercetin treatment decreases DNMTs, in STAT3-dependent manner, increases global acetylation of H3 and H4, and increases the enrichment of acetylated histone H3 and H4 to the promoters of genes related to the apoptosis pathway. a HL60 and U937 cell lines were treated with 50 μmol/L Qu for 48 h. Western blotting was performed for DNMT1, DNMT3a, p-STAT3, and STAT3 proteins. Values are means ± SD of three independent assays. *$p < 0.05$ when compared to cell lines treated with vehicle only. One experiment in three is shown. b The mRNA values are expressed as mean ± SD of three independent experiments. **$p < 0.005$ when compared to HL60 or U937 cells treated with vehicle only. c Confocal microscopy view of HL60 and U937 cells treated with 50 μmol/L Qu for 48 h, incubated with STAT3 antibody and probed with Alexa Fluor 555 (red)-labeled secondary antibody showing a decreased STAT3 expression after treatment. DAPI was used to stain nuclei. d Western blotting analysis of acid-extracted proteins of HL60 cell line exposed to 50 μmol/L Qu for 48 h. Qu treatment increases acetylated levels of H3 and H4. One representative experiment in three is shown. e Treatment of HL60 cells with 50 μmol/L Qu for 48 h. Apoptosis ChIP human PCR array for association of acetylated histone H3 and H4 with the promoters of DAPK1, BCL2L11, APAF1, BAX, BNIP3, and BNIP3L was performed; details are provided in the “Methods” section. f Chromatin immunoprecipitation assay was performed for association of acetylated H3 and H4 histones with the promoters of DAPK1 and BCL2L11 in U937 cells treated with 50 μmol/L Qu for 48 h. Qu treatment caused increased association of acetylated histones H3 and H4 to the promoters of DAPK1 and BCL2L11. g BCL2L11, BAX, APAF1, BNIP3, and BNIP3L mRNA expression levels of HL60 and U937 cells treated with 50 μmol/L Qu for 48 h. The mRNA values are expressed as mean ± SD of three independent experiments. $p < 0.05$, **$p < 0.005$, when compared to HL60 or U937 cells + vehicle
Quercetin enriched H3ac and H4ac in the promoter region of the apoptosis pathway genes and increased their transcription levels

We then wondered whether this increase in acetylation of H3 and H4 also occurred at promoter regions of genes involved in the apoptosis pathway. To verify this, an Apoptosis ChIP human PCR array (SA Biosciences, Qiagen) was performed. HL60 cells treated with 50 μmol/L Qu, for 48 h induced a three- to ten fold enrichment of H3ac and H4ac in the promoter regions of APAF1, BAX, BCL2L11, BNIP3, BNIP3, and DAPK1 (Fig. 2e). We further analyzed the mRNA expression levels of these genes in HL60 and U937 samples treated with 50 μmol/L Qu for 48 h. Qu treatment significantly increased the mRNA levels of all these genes in both cell lines, when compared to control cells (**p < 0.005; *p < 0.05) (Fig. 2g). As the DAPK1 gene promoter is unmethylated and Qu treatment did not induce demethylation of promoter region of BCL2L11 in the U937 cell line, furthermore, Qu treatment upregulated mRNA expression levels of DAPK1 and BCL2L11, we proceeded to investigate whether Qu treatment also induced an enrichment of H3 and H4 acetylation in the promoter regions of DAPK1 and BCL2L11 in U937 cell line.

Using anti acetylated histone H3 and H4 antibodies, followed by RT-PCR with specific primers for DAPK1 and BCL2L11 promoters, a chromatin immunoprecipitation assay was performed. As shown in Fig. 2f, Qu treatment resulted in an increase in the amount of acetylated H3 and H4 associated with both DAPK1 and BCL2L11 promoters.

To confirm that Qu effect on apoptosis was via DAPK1 and BCL2L11, we proceeded to stably inhibit these genes in the cell lines. Further, the transduced cell lines were treated with 50 μmol/L of Qu for 48 h, and apoptosis was detected by flow cytometry. It was observed that in both BCL2L11 shRNA-transduced cell lines, Qu induced apoptosis at a lesser extend when compared to control shRNA-transduced cell lines (*p < 0.05; **p < 0.001) (Fig. 3a–c). It was not possible to accomplish DAPK1 inhibition. For both cell lines, the shRNA lentiviral particle caused too much damage and cells did not recover from transduction.
Quercetin decreases the protein expression of class I histone deacetylases (HDACs) in leukemia cells

Given the data described herein and the fact that HDACs are found in corepressor complexes, we investigated whether the global increment of the acetylation of H3 and H4 affected the expression levels of HDACs. To establish whether Qu treatment alters the protein expression of class I HDACs, we performed Western blot analysis on total cell lysates of HL60 and U937 cells treated with 50 μmol/L Qu for 48 h. Exposure of cells to Qu caused a decrease in the levels of HDACs 1 and 2 (*p < 0.05) (Fig. 4) but not of HDAC 3 and 8 in both cell lines (data not shown).

Quercetin caused proteasome-mediated protein degradation of HDACs in leukemia cells

Furthermore, we determined whether proteasome-mediated degradation was involved in the downregulation of HDACs in cells exposed to Qu. HL60 and U937 cell lines were exposed to 50 μmol/L Qu for 40 h in duplicate, followed by the addition of 10 μmol/L MG132 (an inhibitor of proteasome) to one group and incubated for an additional 8 h. Compared to cells treated only with Qu, MG132 caused a significant increase in HADC expression in both cell lines, demonstrating that Qu treatment downregulates these proteins through proteasome degradation (Fig. 4).

Quercetin downregulates DNMTs and HDACs at the protein levels, in xenograft models

Our in vitro results encouraged us to proceed with an in vivo model; mice were subcutaneously engrafted with HL60 and/or U937 cells, as described in the “Methods” section. Accordingly, Qu treatment almost eliminated DNMT protein levels, and this occurred in part through the downregulation of STAT3 and p-STAT3 at the protein and message levels (*p < 0.05; **p < 0.005) (Fig. 5a). mRNA expression levels of DAPK1, BCL2L11, BAX, BNIP3, BNIP3L, and APAF1 were significantly upregulated compared to those of the control mice (*p < 0.05; **p < 0.005) (Fig. 5b). Moreover, in treated animals, decreased protein levels of HDAC 1 and 2 were also observed (*p < 0.05; **p < 0.005) (Fig. 5c).

Discussion

Epigenetic mechanisms involving modifications in the DNA (methylation) and histones (acetylation, methylation, among others) and their corresponding effects on gene regulation have gained considerable interest. The pattern of modifications on histones and DNA constitutes an epigenetic program that is unique for the cell type and is replicated during successive cell divisions. Alterations of these patterns, particularly in the promoter region of genes, can have profound effects on gene expression. Studies from various cancers have revealed that these alterations affect genes involved in different cellular pathways including apoptosis. Cancer cells have the ability to avoid apoptosis, and this is considered to be one of the prime factors that aid the evolution of cancer [14].

Previously, we have shown that Qu upregulated the expression of pro-apoptotic proteins [12]. Then, in this study, we first performed a screening of the promoter methylation status of 24 apoptosis-related genes in human
HL60 cells. The analysis revealed that five of these genes were highly methylated, including BCL2L11, DAPK1, HRK, TNFRSF21, and TNFRSF25. Furthermore, we validated the methylation pattern of BCL2L11 and DAPK1 using MSP-PCR in samples treated with Qu and observed that the treatment with Qu totally and partially demethylated BCL2L11 and DAPK1, respectively. This demethylation was both dose and time dependent.

DAPK1 (death-associated protein kinase 1) is a pro-apoptotic gene that induces cellular apoptosis in response to internal and external apoptotic stimuli [15]. Therefore, silencing of DAPK1 may result in uncontrolled cell proliferation, indicating that this gene may have a role in tumor suppression. Several studies have demonstrated promoter methylation of DAPK1 in different types of cancer such as renal [15] and cervical cancer [16], B cell lymphoma [17], myelodysplastic syndrome, acute myeloblastic leukemia [18], and chronic myeloid leukemia [19–21]. Our data show that Qu partially demethylates the promoter region of this gene in both a dose- and time-dependent manner, and this may contribute to the increased apoptosis observed in a previous study realized by our group [12]. Consistent with the demethylating effect of Qu, a previous study reported that different concentrations of Qu partially reverted P16INK4a promoter methylation and increased its expression in RKO cells after 5 days of treatment [22].

DNA methylation at the cytosine 5 nucleotide is catalyzed by DNA methyltransferases (DNMTs). This family of proteins is vitally important in epigenetic regulation to modulate gene expression [23]. In our study, Qu treatment almost eliminated DNMT1 and DNMT3a at the protein and message levels, in vitro and in human xenograft models. A previous study, in a gastric cancer cell line, showed that quercetin and isoliquiritigenin decreased DNMT1 and DNMT3a protein levels, causing slight demethylation of the promoter region of the BCL7A gene [24]. We further investigated the expression levels of p-STAT3 and STAT3. STAT3 is a member of a family of transcription factors that regulates proliferation, apoptosis, differentiation, and oncogenesis, and it also regulates DNMT transcription [13]. We found that Qu decreased STAT3 at the protein and at the message level and p-STAT3 at the protein level. The decrease in STAT3 was
also confirmed by confocal microscopy. Unlike this previous study [24], we observed that Qu decreased DNMTs in a STAT3-dependent manner, demonstrating that the mode of action of specific natural compounds depends on their cellular origin.

*BCL2L11* (BCL2-interacting mediator, *(BIM)*) is a member of the BH3-only death activator family and a key determinant of cell fate upon cytokine withdrawal. Its expression is regulated by transcriptional and post-transcriptional mechanisms [25]. *BCL2L11* downregulation has a central role in the survival of clonal progenitors of chronic myeloid leukemia (CML), and this low expression was ascribed to DNA hypermethylation at the gene promoter [26–28]. Moreover, *BCL2L11* re-expression has a key role in BCR-ABL1-expressing cell apoptosis in response to imatinib (IM) [29]. We also observed an upregulation of mRNA levels of this gene in vitro and in vivo (xenograft models), induced by Qu treatment. However, in xenograft models, this upregulation was independent of the demethylation of the promoter region of the gene. This upregulation may be the consequence of the augmentation in H3ac and H4ac observed in the promoter region. Moreover, a study in NPM/ALK+ anaplastic large cell lymphoma (ALCL) cell lines and NPM/ALK+ ALCL lymph node biopsies showed that *BCL2L11* is epigenetically silenced and that treatment with the deacetylase inhibitor trichostatin A restores histone acetylation, strongly upregulates *BCL2L11* expression, and induces cell death [30]. In addition, a study realized by Lee et al. [31] showed that Qu induced apoptosis in leukemia HL60 cells by enhancing the expression of Fas-L, in part through the promotion of H3 acetylation.

We observed in vitro that 50 μmol/L Qu increased the enrichment of H3ac and H4ac by three- to ten fold, after 48 h, in the promoter region of *DAPK1, BCL2L11, BAX, BNIP3, BNIP3L*, and *APA1*, compared to control cells. Further, we analyzed mRNA levels of these genes in vitro and in vivo (samples from xenograft models) and observed that all of them were upregulated, compared to control samples. It is known that histone acetylation mainly occurs at the promoter regions of genes in the process of transcription, whereas histone deacetylation cooperates with gene silencing. Histone deacetylases (HDACs) deacetylate lysine residues of histone tails leading to condensation and closed chromatin formation and transcriptional repression [32].

In the present study, we showed that Qu treatment decreased HDAC1 and HDAC2 protein levels in vitro and in vivo, in the xenograft models, and induced its proteasomal degradation. Many important molecular cell processes are performed by large multisubunit protein complexes, and HDACs do it in the same way. HDAC1 and 2 exist together in at least three distinct multiprotein CoREST complexes [33], and these corepressor complexes are recruited by specific DNA sequences to promoter regions, resulting in transcriptional repression [34].

A potential mechanism to induce apoptosis through histone deacetylase inhibitors (HDACi) is the upregulation of apoptotic genes. HDACi can activate components of the intrinsic pathway, including *BAX* and *APAF1*. *APAF1* has been shown to be upregulated by HDACi including suberoylanilide hydroxamic acid SAHA [35, 36]. *APAF1* binds to cytochrome C, forming the apoptosome and initiating the caspase cascade. *BAX* is a cytosolic protein that undergoes conformational change during apoptosis and migrates to the mitochondria, while *APAF1* cooperates with the release of cytochrome c. In addition, a recent study showed that two HDACi, kendine 92 and SAHA, induced apoptosis in CLL cells by increasing *BAD, BNIP3, BNIP3L, BIM, PLIMA*, and *AIF* mRNA expression levels and decreasing expression of *BCL-W, BCL-2, BFL-1, XIAP*, and *FLIP*. Thus, this study indicates global changes in the apoptosis mRNA expression profile, consistent with the apoptotic outcome [37]. Moreover, Qu has also been shown to inhibit cell cycle and induce apoptosis through inhibition of HDAC and DNMT1, thus suppressing tumor growth and angiogenesis in an induced model of hamster buccal pouch carcinoma [38].

**Conclusions**

In summary, our results showed that enhanced apoptosis, induced by Qu, might be caused in part by its DNA demethylating activity, by HDAC inhibition, and by the enrichment of H3ac and H4ac in the promoter regions of genes involved in the apoptosis pathway, leading to their transcriptional activation. Our results provide the first evidence that Qu acts as an inhibitor of the expression of class I HDAC in leukemia cells. We have also demonstrated that this inhibitory effect of class I HDACs by Qu is due to increased proteasomal degradation. The decrease in HDAC expression coincides with increased global as well as local acetylation of H3 and H4 on the *DAPK1* and *BCL2L11* promoters in both cell lines. Further studies on the effect of Qu on histone acetyltransferases (HATs) and HDAC activity as well as other affected molecular pathways in leukemia cells are encouraged.

**Methods**

**Reagents and antibodies**

Quercetin (> 98% pure) was obtained from Sigma Chemical Co. Antibodies used were as follows: DNMT1, STAT3, HDAC1, HDAC2, acetylated H4 (Ser 1/Lys5/Lys 8/Lys12) actin, DAPK1, BCL2L11, and control shRNA (h) lentiviral particles from Santa Cruz Biotechnology. DNMT3a and p-STAT3 were from Cell Signalling Technology. Acetylated H3 (Lys 9/Lys 18/Lys 23/Lys 27), H3, and H4 were from Abcam Inc. Anti-rabbit, anti-mouse, and anti-goat per-oxidase-conjugated antibodies were from KPL, Inc.
DAPI, Alexa Fluor 555, and Alexa Fluor 488 molecular probes were from Invitrogen. The FITC–Annexin V Apoptosis Detection Kit I was from BD Pharmingen.

**Cell lines and treatment**
HL60 and U937 cell lines were purchased from the American Type Culture Collection (ATCC, Philadelphia, PA) and were cytogenetically tested and authenticated before being frozen. HL60 and U937 cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS), in a 37 °C humidified atmosphere containing CO₂. Qu (≥ 98% pure, Sigma Chemical Co) was dissolved in dimethyl sulfoxide (DMSO) at a final concentration of 0.1% (v/v) in RPMI. The cells were treated with Qu at 50 and 75 μM for 48 or 72 h. Control cells were treated with vehicle alone.

**shRNA lentivirus particle transduction**
HL60 and U937 cells were infected with DAPK1 or BCL2L11 or control shRNA lentivirus particles in the presence of 5 μg/mL Polybrene (Sigma). Infected cells were selected for 14 days in the presence of 2 μg/mL puromycin (Sigma). Expression of DAPK1 and BCL2L11 in infected cells were verified by real-time PCR (RT-PCR) and western blot analysis.

**Detection of apoptosis by flow cytometry**
HL60 and U937 cells transduced with shRNA-targeted BCL2L11 were seeded on 12-well plates and treated with 50 μM Qu. After 48 h, the cells were washed twice with ice-cold PBS and resuspended in a binding buffer containing 1 mg/mL propidium iodide (PI) and 1 mg/mL FITC-labeled annexin V. All specimens were analyzed on FACSCalibur after incubation for 15 min at room temperature in a light-protected area. Ten thousand events were acquired for each sample.

**Confocal microscopy**
Control and treated cells were fixed with 4% PFA (paraformaldehyde) at room temperature for 15 min. Fixed cells were permeabilized with perm buffer (0.2% saponin and 0.1% BSA), blocked with 5% BSA, and incubated overnight in anti-Stat3 antibody at 4 °C. Cells were washed and incubated again with Alexa Fluor 455-conjugated secondary antibody for 2 h at room temperature along with nuclear stain DAPI (4′,6-diamidino-2-phenylindole). Confocal imaging was performed with a Zeiss LSM 710 NLO laser scan confocal microscope using a ×63 objective magnification.

**Methylation analyses**

**Epitect Methyl II PCR Array Human Apoptosis**
For the initial screening of the methylation profile of HL60 cell line, the Epitect Methyl II PCR Array Human Apoptosis was used. Briefly, input genomic DNA was aliquoted into four equal portions and subjected to mock (Mo), methylation sensitive (Ms), methylation dependent (Md), and double (Msd) restriction endonuclease digestion. After digestion, the enzyme reactions were mixed directly with qPCR master mix and aliquoted into a PCR array plate containing pre-dispensed primer mixes. The plate was run then in real-time PCR using specified cycling conditions. The relative fractions of methylated and unmethylated DNA were subsequently determined by comparing the amount in each digest with that of a mock (no enzymes added) digest using the ΔCt method.

**Bisulfite treatment and methylation-specific PCR (MSP-PCR)**
Bisulfite treatment was performed on 1 μg of DNA previously extracted from cells treated with Qu and from frozen samples from xenograft models using the Epitect Bisulfite kit (Qiagen, Valencia, CA, USA). Methylation-specific PCR (MSP) [39] was performed for the promoter region of DAPK and BCL2L11 with primers that were specific for the methylated or unmethylated sequences (M or U sets, respectively; Table 1). The reaction products were separated by electrophoresis on 2% agarose gels.

**Bisulfite sequencing**
Bisulfite sequence assay was performed to demonstrate the methylation status of DAPK1 promoters in the cell line. Genomic DNA from cell lines was isolated with DNeasy kit (Qiagen, Valencia, CA, USA). Genomic DNA was subjected to bisulfite conversion with Epitect Bisulfite kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. The BS primers for DAPK1 promoter region were 5′-GAGGTTTTTGTGATATG GGAATT-3′ (sense) and 5′-TCCACCTCCTAAAAATCTAA TAATT-3′ (antisense), designed by Methyl Primer Express v1.0. Amplified PCR products were purified and sequenced on an ABI Prism 3500 Genetic Analyzer.

**Extraction and expression of acetylated histone proteins**
Leukemia cells HL60 and U937 were treated with 50 μM Qu for 48 h and were harvested and washed twice with ice-cold phosphate-buffered saline (PBS) supplemented with 5 mM sodium butyrate. After washing, cells were resuspended in Triton extraction buffer [PBS containing 0.5% Triton X-100 (vol/vol), 2 mM phenylmethylsulfonyl fluoride, 0.02%(wt/vol) NAN3] and lysed on ice for 10 min with gentle stirring, centrifuged at 2000 r.p.m. for 10 min at 4 °C. The pellet was washed in Triton extraction buffer and then resuspended in 0.2 N HCl. Histones were acid extracted overnight at 4 °C and centrifuged at 2000 r.p.m. for 10 min at 4 °C. Samples were processed for the analysis of histones using immunoblotting.
Western blot analysis
Total cell protein was extracted in RIPA buffer. Protein concentrations were quantified by the Bio-Rad Protein Assay Kit. Equal protein amounts were loaded on 8 to 15% SDS polyacrylamide gels and electrophoretically transferred to nitrocellulose membrane. Nonspecific binding sites were blocked by incubation with a buffer containing Tris (10 mmol/L, pH 7.4), NaCl (150 mmol/L), Tween 20 (0.1%), and fat-free dry milk (5%). Membranes were incubated overnight with a specific primary antibody, at 4 °C, followed by horseradish peroxidase-conjugated secondary antibody, at room temperature for 1 h. Immunoreactivities were visualized by ECL Western Blot Analysis System (Amersham Pharmacia Biotech).

Posttranscriptional histone modifications

Chromatin immunoprecipitation (ChIP)

Apoptosis ChIP human PCR array (SAbiosciences, Qiagen) was used to evaluate whether Qu treatment induces an enrichment of modified histones such as acetylated histone 3 and histone 4 (H3ac, H4ac) in the promoter regions of genes associated to apoptosis pathway. After cross-linking cells with formaldehyde, chromatin containing covalent complexes of genomic DNA and nuclear factors were isolated and sheared by sonication into fragments of between 500 and 1500 bp. The DNA sequences and the posttranslational histone modifications were then immunoprecipitated with specifically antibodies for anti H3ac and H4ac. Next, cross-linking was reversed followed by nucleic acid purification to detect DNA by real-time PCR.

RNA extraction and real-time PCR
The cells treated with Qu and the samples from the xenotransplants were collected, snap frozen, and stored at −80 °C in RNAlater® (Qiagen, Valencia, CA, USA). Total RNA was isolated using the miRNeasy mini kit® (Qiagen). Single-stranded cDNA was synthesized from the RNA using the high capacity cDNA archive kit® (Applied Biosystems, Foster City, CA, USA) following the manufacturer’s protocol.

Quantitative PCR (Sybr Green®) was performed on a 7500 real-time PCR system (Applied Biosystems) using threshold cycle numbers as determined by the RQ Study software (Applied Biosystems). The reactions were run in triplicate, and the threshold cycle numbers were averaged. DNMT1, DNMT3a, STAT3, DAPK1, BCL2L11, BAX, BNIP3, BNIP3L, and APAF1 expressions were measured and normalized using HPRT as an endogenous control. The relative expression was calculated according to the formula $2^{-\Delta\Delta C_{t}}$ [40], and the results were expressed as average gene expression ± SD.

Human tumor xenograft model
Female (NOD.CB17-Prkdcscid/J lineage) 8–11-week-old animals, from the Jackson Laboratory, bred at the Animal Facility Centre at The University of Campinas, under specific pathogen-free conditions, were matched for body-weight before use. Animal experiments were performed following institutional protocols and guidelines of the Institutional Animal Care and Use Committee. Mice were inoculated, s.c, in the dorsal region, on day 0 with 0.1 mL of HL60 or U937 cell suspension (1 × 10⁷ cells/mice). Every 7 days, tumor volumes were evaluated according to the formula: tumor volume (mm³) = (length × width²)/2. Qu treatment (HL60 xenograft model, treated group $n = 5$; U937 xenograft model, treated group $n = 7$) was initiated after tumors reached 100 to 200 mm³ and was administered once every 4 days by i.p injection at 120 mg/kg body weight. The control group (HL60 xenograft model $n = 4$; U937 xenograft model $n = 5$) received equal amounts of vehicle solution, as previously described [41].

### Table 1
Primers used for MSP-PCR and real-time PCR

| Genes     | Primer sense (5′-3′)      | Primer antisense (5′-3′)      |
|-----------|---------------------------|------------------------------|
| BCL2L11   | M AGTATTTCTGGTAAATAATGGGGT | GAATAAATCAAAAAACTCCCAACG     |
|           | U GTATTTTGGTAAATAATGGGGTG  | CAAAAATATCAAAAAACTCCCAACG    |
| DAPK1     | M GGATAGTCGGATGGATATGG    | CCCTCCCAACCGGCA             |
|           | U GAGGAGTATGGTGGATGTTAATGG  | CAAATCCCTCCAAACACCA         |
| APAF1     | CCCAGAGGCTTCCCACCTAATTTG  | CAAAATCACATCAAGATCAAGAAGA    |
| BAX       | TGAGATCTACCAAAGATTGCCA     | AGTCAGCCATCGTTGAGAC         |
| BCL2L11   | TGGTACTGCTCTTCCGGACTG     | TGACCACATCGAGTTAAGAGACGTA   |
| BNIP3     | CCGAAGACATCATCCCTGCGAT    | TTCCGATTGGGCTGGAGCTT         |
| BNIP3L    | CTGGAGTCCACACAGCAAAC      | CCACGGCGGTCTCTGCCCT         |
| DNMT1     | CCATCCGCAATTCTCCA         | CGTTCTCCTGCTTCTCTCT         |
| DNMT3a    | TATTCATGAGGCGCACAAGAGAC   | GGGGTCTGAGGTTAAGAC          |
| STAT3     | CACCTTGGATTGAGTGCAAGGC    | AGGAATCGGCTATATTGCTGGT      |

M methylated, U unmethylated

---

Alvarez et al. Clinical Epigenetics (2018) 10:139
Mice were sacrificed after 21 days. Tumors were then removed, minced, snap frozen, and stored at –80 °C in RNAlater™ (Qiagen, Valencia, CA, USA).

Statistical analysis
The results of the real-time PCR were expressed as means ± SD. All the experiments were realized in triplicate. Student’s t test was used to determine the statistical difference between treated and control group. The data were considered significant if p < 0.05.

Abbreviations
AML: Acute myelogenous leukemia; BCL2L11: BCL-2-interacting mediator, (BIM); CML: Chronic myeloid leukemia; CHlP: Chromatin immunoprecipitation; DAPK1: Death-associated protein kinase 1; DNMTs: DNA methyltransferases; DNMT1: DNA methyltransferase 1; DNMT3a: DNA methyltransferase 3a; HATs: Histone acetyltransferases; H3ac: Acetylated histone 3; H4ac: Acetylated histone 4; HDACs: Histone deacetylases; HDAC1: Histone deacetylase inhibitors; IM: Imatinib; MDSs: Myelodysplastic syndromes; MSP-PCR: Methylation-specific PCR; ncrRNA: Noncoding RNAs; Qu: Quercetin; SAHA: Suberoylanilide hydroxamic acid

Acknowledgements
The authors would like to thank Nicola Conran and Raquel S Foglio for the English revision and Irene Santos and Tereza Salles for their valuable technical assistance.

Funding
This work was supported by grants from the Fundação Armando a Pesquisa do Estado de São Paulo (FAPESP), grant number 2015/21164-7, and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), grant number 150171/2014-5.

Availability of data and materials
Not applicable

Authors’ contributions
MCA and STOS contributed to the conception and design and analysis and interpretation of data. MCA contributed to the development of methodology and acquisition of data. VM, COT, and KPF contributed in the manipulation of animals. MCA and STO contributed to the writing, review, and revision of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 10 July 2018 Accepted: 9 October 2018
Published online: 08 November 2018

References
1. Steensma DP. Myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2015;90(7):969–83.
2. Hatzapediotou M, et al. Epigenetic aberrations during oncogenesis. Cell Mol Life Sci. 2011;68(10):1661–702.
3. Galm O, et al. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 2006;20(1):1–13.
4. Chen J, et al. Leukemogenesis: more than mutant genes. Nat Rev Cancer. 2010;10(1):23–36.
5. Suzuki M, et al. DNA methylation landscapes: provocative insights from epigenomics. Nature Reviews Genet. 2008;9:465–76.
6. Bannister AJ, et al. Regulation of chromatin by histone modifications. Cell Res. 2011;21(3):381–95.
7. Storz G. An expanding universe of noncoding RNAs. Sci. 2002;296(5571):260–3.
8. Beecher GR, et al. Analysis of tea polyphenols. Proc Soc Exp Biol Med. 1999;220(4):267–70.
9. Formica JV, et al. Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol. 1995;33(12):1061–80.
10. Hollman PC, et al. Dietary flavonoids: intake, health effects and bioavailability. Food Chem Toxicol. 1999;37(9):1037–42.
11. Lugli E, et al. Quercetin inhibits lymphocyte activation and proliferation without inducing apoptosis in peripheral mononuclear cells. Leuk Res. 2009;33(11):140–50.
12. Mao V, et al. Multitarget effects of quercetin in leukemia. Cancer Prev Res (Phila). 2014;7(12):1240–50.
13. Herman JG, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821–6.
14. Uvak K, et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt method. Methods. 2001;25:402–8.
15. Wang K, et al. Quercetin induces protective autophagy in gastric cancer cells: involvement of Akt-mTOR and hypoxia-induced factor 1α-mediated signaling. Autophagy. 2011;7(9):966–78.
16. Hino R, et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res. 2009;69:766–74.
17. Hanahan D, et al. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
18. Ahmad S, et al. Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population. Tumor Biol. 2012;33:395–402.
19. Tanaka K, et al. (2014) Gynecological Cancer Registry of Niigata: Promoter methylation of DAPK1, FHT, MGMT, and CDKN2A genes in cervical carcinoma. Int J Clin Oncol 19: 127–132.
20. Kristensen LS, et al. Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing. Sci Rep. 2013;3:2789.
21. Claus N, et al. Quantitative analyses of DAPK1 methylation in AML and MDS. Int J Cancer. 2012;131:E138–42.
22. Katzenellenbogen R, et al. Hypermethylation of the DAP-kinase Cpg island is a common alteration in B-cell malignancies. Blood. 1999;93:3457–53.
23. Imtyaz A, et al. Epigenetic silencing of DAPK1 gene is associated with faster disease progression in India populations with chronic myeloid leukemia. J Cancer Sci Ther. 2013;5:144–9 2013.
24. Qian J, et al. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) Cpg island in Cpg island in chronic myeloid leukemia. Eur J Haematol. 2009;82:119–23 2009. Cpg island in chronic myeloid leukemia. Eur J Haematol: 82: 119–123.
25. Tan S, et al. Quercetin is able to demethylate the p16INK4a gene promoter. Chemotherapy. 2009;55(1):16–10.
26. Klose RJ, et al. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006;31:89–97.
27. Minjung L, et al. Quercetin-induced apoptosis prevents EBV infection. Oncotarget. 2015;6(14):12603–24.
28. Yule R, et al. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47–59.
29. Kurtbara R, et al. Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol. 2004;24(14):6172–83.
30. Achberger KJ, et al. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res. 2005;65(20):9436–44.
31. San José-Estévez E, et al. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukemia. Eur J Cancer. 2009;45(10):1877–89.
32. Kuroda J, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A. 2006;103(40):14097–12.
33. Piazza M, et al. Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/53N3a deacetylating complex. Neoplasia. 2013;15(5):511–22.
34. Lee WJ, et al. Quercetin induces FasL-related apoptosis, in part, through promotion of histone H3 acetylation in human leukemia HL-60 cells. Oncol Rep. 2011;25(2):583–91.
35. Forsberg EC, et al. Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world. Bioessays. 2001;23(9):820–30.
36. Ayer DE. Histone deacetylases: transcriptional repression with SIsNers and NuRDs. Trends Cell Biol. 1999;9:193–8.
37. Yang XJ, et al. Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr Opin Genet Dev. 2003;13:143–53.
38. Peart MJ, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2005;102(10):3697–702.
39. Wang S, et al. Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824. Cell Cycle. 2006;5(15):1662–8.
40. Pérez-Perarnau A, et al. Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells. Epigenetics. 2011;6(10):1228–35.
41. Priyadarsini RV, et al. The flavonoid quercetin modulates the hallmark capabilities of hamster buccal pouch tumors. Nutr Cancer. 2011;63(2):218–26.